SEK640.00
1.23% yesterday
Stockholm, Sep 27, 05:30 pm CET
ISIN
SE0007692850
Symbol
CAMX
Sector
Industry

Camurus Stock price

SEK640.00
-55.50 7.98% 1M
+119.00 22.84% 6M
+102.00 18.96% YTD
+336.80 111.08% 1Y
+473.60 284.62% 3Y
+555.40 656.50% 5Y
+574.00 869.70% 10Y
Stockholm, Closing price Fri, Sep 27 2024
-8.00 1.23%
ISIN
SE0007692850
Symbol
CAMX
Sector
Industry

Key metrics

Market capitalization SEK38.00b
Enterprise Value SEK35.45b
P/E (TTM) P/E ratio 164.99
EV/FCF (TTM) EV/FCF 55.01
EV/Sales (TTM) EV/Sales 22.25
P/S ratio (TTM) P/S ratio 23.85
P/B ratio (TTM) P/B ratio 12.98
Revenue growth (TTM) Revenue growth 8.57%
Revenue (TTM) Revenue SEK1.59b
EBIT (operating result TTM) EBIT SEK237.59m
Free Cash Flow (TTM) Free Cash Flow SEK644.42m
Cash position SEK2.57b
EPS (TTM) EPS SEK3.93
P/E forward 104.71
P/S forward 19.66
EV/Sales forward 18.35
Show more

Is Camurus a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Camurus Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Camurus forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Camurus forecast:

Buy
71%
Hold
29%

Financial data from Camurus

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
1,593 1,593
9% 9%
100%
- Direct Costs 142 142
15% 15%
9%
1,451 1,451
8% 8%
91%
- Selling and Administrative Expenses 482 482
41% 41%
30%
- Research and Development Expense 717 717
47% 47%
45%
252 252
51% 51%
16%
- Depreciation and Amortization 15 15
11% 11%
1%
EBIT (Operating Income) EBIT 238 238
53% 53%
15%
Net Profit 223 223
45% 45%
14%

In millions SEK.

Don't miss a Thing! We will send you all news about Camurus directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.

Head office Sweden
CEO Sven Tiberg
Employees 213
Founded 2004
Website www.camurus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today